Edition:
United States

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

221.40CHF
6:04am EDT
Change (% chg)

CHF0.40 (+0.18%)
Prev Close
CHF221.00
Open
CHF222.20
Day's High
CHF222.60
Day's Low
CHF220.60
Volume
8,302
Avg. Vol
30,791
52-wk High
CHF267.75
52-wk Low
CHF215.40

Select another date:

Thu, May 24 2018

Photo

Vontobel's move for Notenstein shakes up Swiss private banking

ZURICH Private bank Vontobel is buying smaller competitor Notenstein La Roche from Swiss cooperative bank Raiffeisen [RFSHW.UL] for $705 million, the first in what industry insiders expect could be a new wave of consolidation in the sector.

UPDATE 2-Vontobel's move for Notenstein shakes up Swiss private banking

* Industry insiders expect more consolidation among private banks (Adds CEO comments, details, background, shares)

BRIEF-Raiffeisen Schweiz Spokeswoman Says Leonteq Stake Held By Notenstein La Roche Will Move To Raiffeisen

* SPOKESWOMAN SAYS LEONTEQ STAKE HELD BY NOTENSTEIN LA ROCHE WILL MOVE TO RAIFFEISEN Source text for Eikon: Further company coverage:

Vontobel buys private bank Notenstein La Roche for 700 mln Sfr

ZURICH, May 24 Swiss private bank and asset manager Vontobel is buying private bank Notenstein La Roche from Swiss cooperative bank Raiffeisen for 700 million Swiss francs ($705.08 million), the two parties said on Thursday.

BRIEF-Amneal Signs Licensing And Supply Agreement For mAbxience's Biosimilar To Roche's Avastin

* MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES

Roche says has had no contact with Trump lawyer Cohen

ZURICH Roche has had no contact with U.S. President Donald Trump's personal attorney Michael Cohen, the Swiss pharmaceuticals maker's Chief Executive said on Thursday.

Roche says has had no contact with Trump lawyer Cohen

ZURICH, May 17 Roche has had no contact with U.S. President Donald Trump's personal attorney Michael Cohen, the Swiss pharmaceuticals maker's Chief Executive said on Thursday.

Swiss stocks - Factors to watch on May 17

ZURICH, May 17 Here are some of the main factors that may affect Swiss stocks on Thursday:

Roche immunotherapy combination increases lung cancer survival - study

Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.

Roche immunotherapy combination increases lung cancer survival-study

May 16 Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.

Select another date: